Study: Omicron evades some but not all monoclonal antibodies

Several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the omicron variant now sweeping across the United States, researchers reported Jan. 19 in the journal Nature Medicine.

New study suggests most monoclonal antibody treatments are ineffective against Omicron SARS-CoV-2 variant

Why omicron is more infectious than other coronavirus variants

Newest Omicron subvariants can evade boosters, antibody therapies

Viruses, Free Full-Text

FDA Limits Use of Monoclonal Antibodies to Treat COVID-19

Frontiers Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period

Immune Escape Mechanisms of SARS-CoV-2 Delta and Omicron Variants against Two Monoclonal Antibodies That Received Emergency Use Authorization

Frontiers Impact of mAb-induced A475V substitution on viral fitness and antibody neutralization of SARS-CoV-2 omicron variants in the presence of monoclonal antibodies and human convalescent sera

omicron: New Omicron subvariant largely evades neutralising antibodies: Lancet study - The Economic Times

Omicron may sideline two leading drugs against COVID-19